Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs DENTSPLY SIRONA Inc — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.81 (market cap $8.88B), while DENTSPLY SIRONA Inc trades at $8.5 (market cap $1.68B). The key difference: Kymera Therapeutics Inc. Common Stock is far larger — about 5.3× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| KYMR | XRAY | |
|---|---|---|
Market Cap | $8.88B | $1.68B |
Volume | 1,028,790 | 3,968,929 |
Sector | Health | Health |
52-Week High | $127.31 | $14.68 |
52-Week Low | $55.80 | $8.44 |
Typical Hold Time | 0 Days | 72 Days |
Enterprise Value | $8.27B | $3.76B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
DENTSPLY SIRONA (XRAY) trades at $8.51, near its 52-week low, with a bearish technical outlook. The company reported a net loss of $598 million in 2025, with negative profit margins and declining revenue. Recent Q2 2026 earnings beat estimates, but sales fell 4.1% year-over-year. Analyst consensus is mixed, with a $12.50 price target but more hold than buy ratings.
The stock faces significant headwinds from weak profitability and competitive pressures, though cost-cutting and digital dentistry investments offer long-term potential. High debt levels and ongoing margin pressure present substantial risks. Upside depends on successful execution of the turnaround plan and stabilization of core dental markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
